par THERACLION (EPA:ALTHE)
Inside Information / Other news releases
MONTHLY INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPRISING THE SHARE CAPITAL
Article 223-16 du Règlement Général de l’Autorité des marchés financiers
Malakoff - France, October 10, 2025
Place de cotation : Euronext Growth Paris
Éligible PEA PME
Code ISIN : FR0010120402
Site Internet : www.theraclion.com
Voting rights :
Date | Total number of shares of Theraclion (3) | Total number of theoretical voting rights of Theraclion ( (1) | Total number of real voting rights of Theraclion (2) |
30/09/2025 | 58 081 079 | 72 881 292 | 72 139 083 |
(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulations.
(2) Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.
(3) Of which 10 677 175 shares from the conversion of Convertible Bonds (OCA) subscribed during the issues of February 20, and March 26, 2025 and 346,620 shares resulting from the subscription of warrants (BSA) issued on June 15, 2023.
About Theraclion
Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound. High Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and enables patients to return to their daily activities immediately. The HIFU treatment method concentrates therapeutic ultrasounds on an internal focal point from outside the body.
Theraclion develops the HIFU, CE-marked, platform for varicose veins treatment SONOVEIN®, which has the potential to replace millions of surgical procedures every year. In the United States, SONOVEIN® is an investigational device limited to investigational use; it is not available for sale in the U.S.
Based in Malakoff (Paris), the Theraclion team is made up of some 30 people, most of them involved in technological and clinical development.
For more information, please visit www.theraclion.com and follow the LinkedIn account.
Theraclion contact
Martin Deterre
Chief Executive Officer contact@theraclion.com
Page 1 sur 1